Mutual associations among responsiveness to differential diagnostic tests for Cushing’s disease, tumor size, and somatostatin receptor 5 expression in corticotroph tumors
Open Access
- 1 January 2025
- journal article
- research article
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 72 (1) , 93-102
Abstract
There are differences in the responsiveness to differential diagnostic tests for Cushing’s disease (CD), corticotroph tumor size, and the somatostatin receptor (SSTR) 5 expression in corticotroph tumors between CD patients. The differences in SSTR5 expression are particularly significant for identifying therapeutic targets for CD. However, prospective predictors of SSTR5 expression remain unclear. Thus, our objective was to elucidate the relationships among these clinical characteristics of CD, including SSTR5 expression. In 27 hospitalized patients with CD at Osaka University Hospital, Osaka, Japan, associations between corticotroph tumor diameter, the response of ACTH and cortisol to differential diagnostic tests for CD (CRH, desmopressin [DDAVP], and high-dose dexamethasone suppression test [HDDST]), the ACTH/cortisol index, and the SSTR5 immunoreactive score were retrospectively investigated. The response to differential diagnostic tests, ACTH/cortisol index, tumor diameter, and SSTR5 expression were significantly related (vs. tumor diameter [CRH: r = –0.54; DDAVP: r = –0.54; HDDST r = –0.67; ACTH/cortisol index: r = 0.76; SSTR5: r = –0.61], vs. CRH [DDAVP: r = 0.63, HDDST: r = 0.72, ACTH/cortisol index: r = –0.45; SSTR5: r = 0.56], vs. DDAVP [HDDST: r = 0.66; ACTH/cortisol index: r = –0.46; SSTR5: r = 0.76], vs. HDDST [ACTH/cortisol index: r = –0.62; SSTR5: r = 0.77], ACTH/cortisol index vs. SSTR5: r = –0.67). The areas under the receiver operating characteristic curve for the prediction of high SSTR5 expression via the CRH test, DDAVP test, HDDST, ACTH/cortisol index, and tumor diameter were 0.79, 0.87, 0.80, 0.71, and 0.71, respectively. Tests for differential diagnosis of CD, the ACTH/cortisol index, and the corticotroph tumor diameter have the potential for identifying SSTR5 expression in corticotroph tumors. These parameters may reflect the biological characteristics of corticotroph tumors.Keywords
Funding Information
- Health Labour Sciences Research Grant (23FC1042)
This publication has 18 references indexed in Scilit:
- Responsiveness to DDAVP in Cushing’s disease is associated with USP8 mutations through enhancing AVPR1B promoter activityPituitary, 2022
- Integrative Clinical, Radiological, and Molecular Analysis for Predicting Remission and Recurrence of Cushing DiseaseThe Journal of Clinical Endocrinology & Metabolism, 2022
- Global Cushing’s disease epidemiology: a systematic review and meta-analysis of observational studiesJournal of Endocrinological Investigation, 2022
- Indication to dynamic and invasive testing in Cushing’s disease according to different neuroradiological findingsJournal of Endocrinological Investigation, 2021
- Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cellsMolecular and Cellular Endocrinology, 2021
- Somatostatin receptor expression and patients’ response to targeted medical treatment in pituitary tumors: evidences and controversiesJournal of Endocrinological Investigation, 2020
- Clinical and biochemical manifestations of Cushing’sPituitary, 2015
- Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivoMolecular and Cellular Endocrinology, 2014
- Reassessment of sst5 Somatostatin Receptor Expression in Normal and Neoplastic Human Tissues Using the Novel Rabbit Monoclonal Antibody UMB-4Neuroendocrinology, 2011
- Plasma corticotrophin response to desmopressin in patients with Cushing’s disease correlates with the expression of vasopressin receptor 2, but not with that of vasopressin receptor 1 or 3, in their pituitary tumoursClinical Endocrinology, 2011